drugset / Trial / NCT03416335
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A). The combination arm has Dose Escalation (Part B) only.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2022-12-20
- Completion
- 2022-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GURETOLIMOD | Small molecule | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |